Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study: ESMO open

E. Blondeaux, A.R. Ferreira, F. Poggio, F. Puglisi, C. Bighin, F. Sottotetti, F. Montemurro, E. Poletto, A. Lai, V. Sini, G. Minuti, S. Mura, A. Fontana, P. Fregatti, B. Cardinali, M. Lambertini, L. Del Mastro

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: In the prepertuzumab era, we evaluated the clinical outcomes of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who underwent first-line trastuzumab-based or lapatinib-based therapy according to prior exposure to (neo)adjuvant trastuzumab. MATERIALS AND METHODS: In this multicentre retrospective cohort study conducted in 14 Italian centres of the Gruppo Italiano Mammella, consecutive patients undergoing first-line trastuzumab or lapatinib-based therapy were included. Analyses were performed according to the type of first-line therapy for metastatic disease (trastuzumab or lapatinib). Dichotomous clinical outcomes were analysed using logistic regression and time-to-event outcomes using Cox proportional hazard models controlling for relevant demographic, clinicopathological and therapy characteristics. RESULTS: Out of 450 patients included in the study, 416 (92%) received trastuzumab and 34 (7.5%) lapatinib. As compared with the trastuzumab cohort, more patients in the lapatinib cohort had a trastuzumab-free interval
Original languageEnglish
Article numbere000719
Number of pages9
JournalESMO Open
Volume5
Issue number4
DOIs
Publication statusPublished - 2020

Keywords

  • first-line therapy
  • HER2-positive
  • lapatinib
  • metastatic breast cancer
  • trastuzumab

Fingerprint Dive into the research topics of 'Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study: ESMO open'. Together they form a unique fingerprint.

Cite this